MissionIR Articles
-
Annovis Bio Inc. (NYSE: ANVS) Announces FDA Approval to Transition to New Form of Buntanetap for Future Clinical Trials
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders like Alzheimer’s and Parkinson’s, just announced that the U.S. Food and Drug Administration (“FDA”) has given approval for Annovis…
-
SuperCom Ltd. (NASDAQ: SPCB) EM Technology Highly Competitive in Expanding Field of Court-administered Offender Monitoring
The use of electronic monitoring (“EM”) to track the whereabouts of domestic violence or other offenders has risen steadily over the last 40-plus years since the state of Florida’s Department of Corrections became the first…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives Order for Mullen Campus EVs from Leading Transportation and Logistics Company
Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for four Mullen Campus electric vehicles from DB Schenker, one of the world’s leading transportation and logistics companies. According to the announcement,…
-
Clene Inc. (NASDAQ: CLNN) Discusses Important Developments of CNM-Au8(R) and Its Novel Technology During Xtalks Podcast
Xtalks Life Science Podcast recently featured Karen S. Ho, PhD, Vice President of Translational Medicine for Clene (NASDAQ: CLNN), a late-stage biopharmaceutical company focused on protecting mitochondrial health and neuronal function to treat neurodegenerative diseases. In…
-
MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Receives PO from European Distributor for 29 Mullen GOs
Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, has received an order for 29 Mullen GOS from one of its newest European distribution partners. The order for the GOs, which are Mullen’s commercial micro-urban-delivery…
-
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives US Patent for Methods of Treating Acute Traumatic Brain Injury with Its Lead Drug Candidate
Annovis Bio (NYSE: ANVS), a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent covers methods of…
-
InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration
Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality…
-
SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) – Offering Sustainable and Humane Solution to NYC’s Rat Problem
Following New York City’s recent hard stance in the fight against rodents in the city, its leadership has been under backlash, mainly from People for the Ethical Treatment of Animals (“PETA”). The organization blamed the…
-
MissionIRNewsBreaks – Mullen Automotive Inc.’s (NASDAQ: MULN) Subsidiary Announces Warranty Coverage for B4 Chassis Cab
Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has announced that its subsidiary, Bollinger Motors, released its full warranty coverage on the Bollinger B4 Chassis Cab, the company’s all-new, all-electric Class 4 commercial…
-
Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members
Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to…
-
Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature
Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like ALS (amyotrophic lateral sclerosis) and multiple sclerosis (“MS”). In a recent Emerging Growth Conference 73 – Biotech…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way…
-
D-Wave Quantum Inc. (NYSE: QBTS) Adds Second Annealing Quantum Computer in the U.S. and Unveils New Hybrid Quantum Solver
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, continues to make strides in the development and deployment of quantum computing technology. The company recently announced two major advancements: the introduction…
-
SuperCom Ltd.’s (NASDAQ: SPCB) Latest $2.9 Million Government EM Contract Shows Continuing Appeal of its Technology
SuperCom (NASDAQ: SPCB), a global identity technology provider, reported on July 11 that the company has received new orders from European governments valued at $2.9 million, the third set of orders from European clients in…
-
Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease and Parkinson’s Disease, has released new data from its Phase III study of buntanetap for…
-
Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction
Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and protecting neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple…
-
D-Wave Quantum Inc. (NYSE: QBTS) Reveals Findings of Hyperion Research Quantum Optimization ROI Study and Announces Nomination for Technology Impact Awards
D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services, and the world’s first commercial supplier of quantum computers, recently announced the findings of a recent study it commissioned with Hyperion Research…
-
MissionIRNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including…
-
Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Issuance of Three New Patents, Growing Portfolio to 46 Granted Patents Worldwide
Lexaria’s multi-patented DehydraTECH(TM) “drug delivery platform technology” offers proven increased bioavailability, enhancing the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption…
-
Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap
Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is continuing to make significant…
Search Articles
Latest Articles
- Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ): Advancing a Premier North American Copper District
- MissionIRNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
- Safe Pro Group Inc. (NASDAQ: SPAI) Advanced AI Patent Protections with Notification Publications in Australia, Israel, and the European Region
- MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment
- MissionIRNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Prices $7 Million Public Offering of Common Stock and Pre-Funded Warrants